Entity

Time filter

Source Type


Saini A.K.,University of Saskatchewan | Saini A.K.,Helix BioPharma Corporation | Tyler R.T.,University of Saskatchewan | Shim Y.,University of Saskatchewan | Reaney M.J.T.,University of Saskatchewan
BMC Research Notes | Year: 2011

Background: Allyl isothiocyanate (AITC) from mustard is cytotoxic; however the mechanism of its toxicity is unknown. We examined the effects of AITC on heat shock protein (HSP) 70 expression in Caenorhabditis elegans. We also examined factors affecting the production of AITC from its precursor, sinigrin, a glucosinolate, in ground Brassica juncea cv. Vulcan seed as mustard has some potential as a biopesticide. Findings. An assay to determine the concentration of AITC in ground mustard seed was improved to allow the measurement of AITC release in the first minutes after exposure of ground mustard seed to water. Using this assay, we determined that temperatures above 67°C decreased sinigrin conversion to AITC in hydrated ground B. juncea seed. A pH near 6.0 was found to be necessary for AITC release. RT-qPCR revealed no significant change in HSP70A mRNA expression at low concentrations of AITC (< 0.1 M). However, treatment with higher concentrations (> 1.0 M) resulted in a four- to five-fold increase in expression. A HSP70 ELISA showed that AITC toxicity in C. elegans was ameliorated by the presence of ground seed from low sinigrin B. juncea cv. Arrid. Conclusions: AITC induced toxicity in C. elegans, as measured by HSP70 expression. Conditions required for the conversion of sinigrin to AITC in ground B. juncea seed were determined. The use of C. elegans as a bioassay to test AITC or mustard biopesticide efficacy is discussed. © 2011 Reaney et al; licensee BioMed Central Ltd.


A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.


Trademark
Pharmascience Inc., Helix Biopharma Corporation and Intercon Pharma Ltd. | Date: 2010-07-02

bowel evacuant preparations; laxatives.


This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.


This invention relates to biphasic lipid-vesicle compositions and methods for treating cervical displasia by intravaginal delivery.

Discover hidden collaborations